Please login to the form below

Not currently logged in
Email:
Password:

GSK unveils board and committee changes

Manvinder Singh Banga named as a non-executive director

edit-manvinder-singh-bangaGlaxoSmithKline has appointed Manvinder Singh (Vindi) Banga as a non-executive director, effective from September 1 of this year.

Banga will also succeed Sir Deryck Maughan as senior independent director from May 5 2016. Maughan will not seek re-election and will retire from the board.

Banga held numerous roles at Unilever over 23 years, including his most recent position as president of the global foods, home and personal care business as well as being a member of the firm's executive board.

Commenting on the appointment, Sir Philip Hampton, chairman designate at GSK, said: “I am delighted that Vindi is joining the board.

“Vindi brings with him many years of experience and a track record of delivering outstanding performance in a highly competitive global consumer-focused industry which will be invaluable to GSK. My colleagues and I very much look forward to welcoming him to the board.”

GSK additionally announced Urs Rohner, non-executive director, has been named as chairman of the remuneration committee and Lynn Elsenhans, also a non-executive director, has been appointed as chairman of the corporate responsibility committee, both effective from May 8 2015.

19th May 2015

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Weber Shandwick

At Weber Shandwick, engagement has always been the cornerstone of health communications.We make health matter. Health is a basic human...

Latest intelligence

Enabling market access through outcomes-based pricing
Outcomes-based pricing is a potential solution to create a link between product price and real-world outcomes, while at the same time facilitating patient access to new and innovative medicines....
Five companies 20 for 2020
20 for 2020 – Five pharma companies to watch
As a new decade gets into gear, we take a look at five pharma companies that have a lot riding on 2020...
The growing clinical importance of patient-reported outcomes (PROs)
Traditionally, the success or otherwise of medical treatments has been assessed by mortality or clinical assessments of health. However, patient self-reports of health are increasingly seen as central to the...

Infographics